|
| 38030749 | Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. | Br J Cancer | 2024 |
| 38030749 | Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. | Br J Cancer | 2024 |
| 37867114 | Sexual Dysfunction in Patients With Metastatic Breast Cancer. | Clin Breast Cancer | 2024 |
| 37867114 | Sexual Dysfunction in Patients With Metastatic Breast Cancer. | Clin Breast Cancer | 2024 |
| 36346689 | NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects. | Clin Cancer Res | 2023 |
| 36245263 | Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers. | J Genet Couns | 2023 |
| 36040183 | Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. | Cancer Med | 2023 |
| 36346689 | NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects. | Clin Cancer Res | 2023 |
| 38019076 | Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. | Cancer Res Commun | 2023 |
| 38014910 | Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry. | Cancer Res Commun | 2023 |
| 37733366 | Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. | JAMA Oncol | 2023 |
| 37718511 | BRCA1 frameshift variants leading to extended incorrect protein C termini. | HGG Adv | 2023 |
| 37561108 | Changes in amount and intensity of physical activity over time in breast cancer survivors. | JNCI Cancer Spectr | 2023 |
| 37287928 | Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile. | Front Oncol | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37210429 | Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. | Breast Cancer Res Treat | 2023 |
| 36824750 | Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. | Res Sq | 2023 |
| 36823213 | MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogramming. | Commun Biol | 2023 |
| 36635351 | PDJ amplicon in triple negative breast cancer. | Sci Rep | 2023 |
| 36571512 | The risks of cancer in older women with BRCA pathogenic variants: How far have we come? | Cancer | 2023 |
| 37072398 | Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. | Nat Commun | 2023 |
| 37451831 | Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. | J Med Genet | 2023 |
| 37253112 | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C. | Cancer Res | 2023 |
| 36623243 | Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>. | J Clin Oncol | 2023 |
| 36993608 | Clinical Outcomes and Prognostic Factors in Triple-Negative Invasive Lobular Carcinoma of the Breast. | Res Sq | 2023 |
| 37433282 | Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. | Cancer Cell | 2023 |
| 37503126 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum. | medRxiv | 2023 |
| 37493628 | Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 37718511 | BRCA1 frameshift variants leading to extended incorrect protein C termini. | HGG Adv | 2023 |
| 38019076 | Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. | Cancer Res Commun | 2023 |
| 37561108 | Changes in amount and intensity of physical activity over time in breast cancer survivors. | JNCI Cancer Spectr | 2023 |
| 38014910 | Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry. | Cancer Res Commun | 2023 |
| 37503126 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum. | medRxiv | 2023 |
| 37733366 | Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. | JAMA Oncol | 2023 |
| 37493628 | Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 36993608 | Clinical Outcomes and Prognostic Factors in Triple-Negative Invasive Lobular Carcinoma of the Breast. | Res Sq | 2023 |
| 37287928 | Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile. | Front Oncol | 2023 |
| 37253112 | Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C. | Cancer Res | 2023 |
| 37451831 | Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. | J Med Genet | 2023 |
| 37210429 | Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. | Breast Cancer Res Treat | 2023 |
| 37072398 | Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. | Nat Commun | 2023 |
| 37433282 | Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. | Cancer Cell | 2023 |
| 36623243 | Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>. | J Clin Oncol | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 36571512 | The risks of cancer in older women with BRCA pathogenic variants: How far have we come? | Cancer | 2023 |
| 36635351 | PDJ amplicon in triple negative breast cancer. | Sci Rep | 2023 |
| 36824750 | Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. | Res Sq | 2023 |
| 36823213 | MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogramming. | Commun Biol | 2023 |
| 36245263 | Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers. | J Genet Couns | 2023 |
| 36040183 | Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. | Cancer Med | 2023 |